Foregut bypass vs. restrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals

Abstract

Background: Bariatric surgery represents an important treatment option for severely obese patients with nonalcoholic fatty liver disease (NAFLD). However, there remains inadequate data regarding the effects of different bariatric procedures on various NAFLD parameters, especially for histological outcomes. Thus, this meta-analysis aimed to compare the effects of restrictive bariatric procedures and foregut bypass on the metabolic, biochemical, and histological parameters for patients with NAFLD.Methods: Medline and Embase were searched for articles relating to bariatric procedures and NAFLD.Pairwise meta-analysis was conducted to compare efficacy of bariatric procedures pre-vs. post-procedure with subgroup analysis to further compare restrictive against foregut bypass procedures.Results: Thirty-one articles involving 3,355 patients who underwent restrictive bariatric procedures (n=1,460) and foregut bypass (n=1,895) were included. Both foregut bypass (P<0.01) and restrictive procedures (P=0.03) significantly increased odds of fibrosis resolution. Compared to restrictive procedures, foregut bypass resulted in a borderline non-significant decrease in fibrosis score (P=0.06) and significantly lower steatosis score (P<0.001). For metabolic parameters, foregut bypass significantly lowered body mass index (P=0.003) and low-density lipoprotein (P=0.008) compared to restrictive procedures. No significant differences were observed between both procedures for aspartate aminotransferase (P=0.17) and alkaline phosphatase (P=0.61). However, foregut bypass resulted in significantly lower gamma-glutamyl transferase than restrictive procedures (P=0.01) while restrictive procedures resulted in significantly lower alanine transaminase than foregut bypass (P=0.02).

De novo metabolic syndrome after liver transplantation: a meta-analysis on cumulative incidence, risk factors, and outcomes

“…More importantly, the titration of dosages and choice of immunosuppressants should be a personalized one-where physicians should factor into their decisions a patient's baseline metabolic, immunogenic, infection and/or tumor recurrence risk and potential adverse effects of certain immunosuppressants such as renal impairment, components of MS, and cytopenia. More recently, bariatric surgery has been demonstrated to achieve substantial and durable weight loss among obese individuals with NAFLD [52] and may be a viable management option to improve post-LT metabolic and cardiovascular risk profiles in high-risk patients. At present, there are no evidence-based guidelines recommending the screening of MS after LT.…”

Metabolic dysfunction-associated steatotic liver disease: A silent pandemic

“…It can improve both histological characteristics of NASH as well as mortality due to cardiovascular complications[ 57 ]. Lim et al [ 58 ] studied the usefulness of endoscopic bariatric therapies such as intragastric balloon, endoscopic sleeve gastroplasty, and duodenojejunal bypass liner in reducing weight and found better results as compared to standard medical therapy. With extensive research into the therapeutic options in the pipeline, treatment strategies for NAFLD treatment are promising[ 59 ].…”

Editorial: The heart of NAFLD

“…The concerted approach to the reduction of the NAFLD and CVD burden was succinctly consolidated by the study, with the continued medical education program on NAFLD that encompass the best clinical practices tailored to primary care setting, that can improve confidence in the management of NAFLD-related conditions (Papadakis et al). With the plethora of upcoming NASH therapeutic options (33-35) in the pipeline, treatment strategies in improving both liver-related outcomes and concomitant cardiometabolic profile are promising (32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43).…”